Loading…
AbCellera Biologics Inc. is projected to rise to $6.90 by 2027, a +27% move from its current price of $5.44. ABCL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.20 | $5.45 | $5.70 | +0.10% |
| May 30 | $5.11 | $5.45 | $5.82 | +0.21% |
| May 31 | $5.04 | $5.46 | $5.91 | +0.31% |
| Jun 1 | $4.98 | $5.46 | $5.99 | +0.42% |
| Jun 2 | $4.93 | $5.47 | $6.07 | +0.52% |
| Jun 3 | $4.89 | $5.47 | $6.13 | +0.63% |
| Jun 4 | $4.85 | $5.48 | $6.19 | +0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.85 | $5.48 | $6.19 | +0.74% |
| Week 2 | $4.64 | $5.52 | $6.57 | +1.48% |
| Week 3 | $4.50 | $5.56 | $6.88 | +2.22% |
| Week 4 | $4.38 | $5.60 | $7.16 | +2.97% |
| Week 5 | $4.29 | $5.64 | $7.42 | +3.73% |
| Week 6 | $4.21 | $5.68 | $7.68 | +4.49% |
| Week 7 | $4.14 | $5.73 | $7.92 | +5.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbCellera Biologics Inc. is a healthcare company that engages in discovering and developing antibody based medicines for indications with unmet medical need in the United States. Its lead product ABCL635 is a non-hormonal medicine in Phase 2 clinical trials to treat moderate-to-severe vasomotor symptoms.
ABCL575 is a fully human, half-life extended monoclonal antibody in Phase 1 clinical trials for treating T-cell-mediated autoimmune conditions such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company and AbbVie Inc. It also has partnership agreements with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. trades under the symbol ABCL and operates in the healthcare sector. The current price is $5.20, and the company has a market capitalization of $1.59B, with a rank of 2186.
The price outlook is represented by a year by year forecast that shows a path higher, with the 2026 average price at $5.20 and a wide range in subsequent years. Specific annual averages include 2027 $6.52, 2028 $6.64, 2029 $7.13, 2030 $8.68, 2031 $12.58, 2032 $14.33, 2033 $14.40, 2034 $15.50, 2035 $15.17, 2040 $28.89, and 2050 $63.30; with max values reaching as high as $145.58 in 2050. The forecast also shows a shift in sentiment from Neutral in 2026 to Bullish from 2027 onward, and cumulative ROI rising to 1117.2% by 2050.
A major floor 48.9% below — a decisive break under it would weaken the trend.
The nearest floor, 29.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 19.9% above — clearing it would confirm fresh momentum.
Key ABCL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABCL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.13 | Buy | $5.13 | Buy |
| MA 10 | $4.71 | Buy | $4.92 | Buy |
| MA 20 | $4.70 | Buy | $4.69 | Buy |
| MA 50 | $4.07 | Buy | $4.27 | Buy |
| MA 100 | $3.85 | Buy | $4.06 | Buy |
| MA 200 | $4.16 | Buy | $3.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.78 | Neutral |
| Stoch RSI (14) | 72.97 | Neutral |
| CCI (20) | 119.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 3.82 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.84 | Buy |
| Awesome (5,34) | 0.76 | Buy |
| Ultimate (7,14,28) | 78.34 | Sell |
| Momentum (10) | 0.49 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 5.56 | Sell |
| ADX (14) | 25.15 | Buy |
| ATR (14) | 0.20 | Info |
The 30 day technical picture is Bullish overall. RSI14 sits at 60, signaling room to move higher without being overbought. The short-term moving averages are SMA50 at $3.99 and SMA200 at $4.15, providing near-term support and resistance levels around the current price.
Key intra-month levels include support at $3.66 and resistance at $5.25. The 30-day range spans from $3.77 to $7.17, indicating a broad pricing corridor over the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.78 | $5.44 | $8.06 | 0% | Neutral | |
| $5.10 | $6.90 | $10.06 | +27% | Bullish | |
| $5.17 | $7.34 | $11.31 | +35% | Bullish | |
| $5.32 | $7.89 | $12.69 | +45% | Bullish | |
| $6.26 | $9.66 | $16.10 | +78% | Bullish | |
| $8.88 | $14.19 | $24.39 | +161% | Bullish | |
| $9.69 | $16.03 | $28.33 | +195% | Bullish | |
| $9.54 | $16.31 | $29.53 | +200% | Bullish | |
| $10.14 | $17.88 | $33.13 | +229% | Bullish | |
| $9.60 | $17.46 | $33.02 | +221% | Bullish | |
| $16.29 | $34.27 | $70.69 | +530% | Bullish | |
| $34.16 | $75.90 | $174.57 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.78 | $5.44 | $6.48 | +0.00% |
| June 2026 | $4.91 | $5.86 | $7.22 | +7.71% |
| July 2026 | $4.95 | $5.98 | $7.54 | +2.14% |
| August 2026 | $4.75 | $5.81 | $7.44 | -2.94% |
| September 2026 | $4.79 | $5.92 | $7.68 | +1.84% |
| October 2026 | $4.95 | $6.16 | $8.10 | +4.20% |
| November 2026 | $4.83 | $6.07 | $8.07 | -1.52% |
| December 2026 | $4.75 | $6.01 | $8.06 | -1.04% |
Click any year to see its month-by-month ABCL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ABCL price prediction for 2026 points to an average of $5.44 (low $2.78, high $8.06) — a potential gain of 0% on today's $5.44. A consolidation phase looks the most probable path here.
In 2027, ABCL is projected to trade between $5.10 and $10.06, averaging $6.90 — a potential gain of +27% from today's $5.44. That is up +27% on the projected 2026 average. Momentum favours further upside here.
AbCellera Biologics Inc.'s 2028 outlook centres on $7.34, within a $5.17 to $11.31 range. That is up +6% on the projected 2027 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ABCL could reach as high as $12.69, with a base case around $7.89 and support toward $5.32 — roughly +45% from $5.44. Momentum favours further upside here.
Expect ABCL to range from $6.26 to $16.10 through 2030. The $9.66 average target implies a +78% move from current prices. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ABCL price prediction for 2031 points to an average of $14.19 (low $8.88, high $24.39) — a potential gain of +161% on today's $5.44. Momentum favours further upside here.
In 2032, ABCL is projected to trade between $9.69 and $28.33, averaging $16.03 — a potential gain of +195% from today's $5.44. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AbCellera Biologics Inc.'s 2033 outlook centres on $16.31, within a $9.54 to $29.53 range. That is up +2% on the projected 2032 average. That marks a +200% change versus current levels. Momentum favours further upside here.
By 2034, ABCL could reach as high as $33.13, with a base case around $17.88 and support toward $10.14 — roughly +229% from $5.44. Buyers look set to stay in control over this stretch.
Expect ABCL to range from $9.60 to $33.02 through 2035. The $17.46 average target implies a +221% move from current prices. That is -2% versus the projected 2034 average. Momentum favours further upside here.
The ABCL price prediction for 2040 points to an average of $34.27 (low $16.29, high $70.69) — a potential gain of +530% on today's $5.44. Buyers look set to stay in control over this stretch.
In 2050, ABCL is projected to trade between $34.16 and $174.57, averaging $75.90 — a potential gain of +13.0x from today's $5.44. That is up +121% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABCL today (≈ 183.823529 ABCL) could be worth
$13,952.32
+$12,952.32 (+1295%) by 2050 · US Dollar
Based on the average projected ABCL price of $75.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABCLwould be worth at today's price.
$1,000 invested in ABCL on May 27, 2025 (≈ 505.0505 ABCL) would be worth
$2,747.47
+$1,747.47 (+174.7%) today · 2.75× · US Dollar
Based on a ABCL entry price of $1.98 vs. today's $5.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.57 | $1,190.37 | +19.0% |
| 1 month ago | $4.16 | $1,307.69 | +30.8% |
| 3 months ago | $3.59 | $1,515.32 | +51.5% |
| 6 months ago | $3.73 | $1,458.45 | +45.8% |
| 1 year ago | $1.98 | $2,747.47 | +174.7% |
| All time (5.0y) ago | $26.44 | $205.75 | -79.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABCL forecast.
Our base-case forecast reaches $11.00 around 2031.
Implied market cap at $11.00: $3.36B
The multi-year forecast paints a strong upward trajectory for ABCL, with the average price rising from $5.20 in 2026 to $63.30 by 2050. The projected maxes include $14.70 in 2030, $61.00 in 2040, and $145.58 in 2050, illustrating substantial upside potential under the forecast assumptions.
Forecasted sentiment is Neutral in 2026 and Bullish from 2027 onward, with annual ROIs climbing from 0% in 2026 to 25.4% in 2027, 27.8% in 2028, 37.2% in 2029, then 66.8% in 2030 and 455.6% by 2040, culminating at 1117.2% in 2050. The year-by-year averages show a steady march higher, reflecting an overall bullish longer-term outlook despite the near-term neutrality.
These figures are estimates and not guarantees, and actual results may differ due to market conditions and other factors.
Tap a question to reveal the answer.
The 2030 average price is $8.68, with a 2030 min of $5.52 and a max of $14.70. The 2030 ROI is 66.8% and the sentiment is Bullish.
Forecasts show Neutral sentiment in 2026 and Bullish sentiment from 2027 onward, with the average price rising to $63.30 by 2050 and ROI reaching 1117.2% in 2050.
Yes. The forecast max prices include $61.00 in 2040 and $145.58 in 2050, indicating a path to and beyond the $60 level under the projected scenario.
Current price is $5.20 and the market cap is $1.59B. The stock is ranked 2186.
The 30 day range is $3.77 to $7.17.
AbCellera Biologics Inc. Community Discussion
0Share your AbCellera Biologics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.